The association of proopiomelanocortin polymorphisms with the risk of major depressive disorder and the response to antidepressants via interactions with stressful life events

Hun Soo Chang, Eun Soo Won, Hwa Young Lee, Byung-Joo Ham, Yong Gu Kim, Min-Soo Lee

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Hyperactivity of the hypothalamic–pituitary–adrenal (HPA) axis is among the most consistent neuroendocrine abnormalities in major depressive disorder (MDD). The peptide adrenocorticotropin hormone (ACTH) mediates HPA axis function during stress and is encoded by the proopiomelanocortin (POMC) gene polycistronically. After screening 39 POMC polymorphisms, we evaluated the association of polymorphisms with susceptibility to MDD in 145 MDD patients and 193 normal subjects; in patients, we also evaluated the response to treatment with antidepressants. Additionally, we investigated the role of gene–environment interaction between POMC haplotypes and stressful life events (SLE) in the treatment response. Although genotypes and haplotypes were not significantly associated with the risk of MDD, non-remitters were more likely to carry haplotype 1 (ht1) and to have no ht2 than were remitters (corrected P = 0.010–0.035). Although observations were limited in patients without SLE, a significant haplotype–SLE interaction was observed (P = 0.020). Additionally, at 1, 2, and 8 weeks of treatment, the 21-item Hamilton Depression Rating scores of MDD subjects with POMC ht2 were significantly (P = 0.003–0.044) lower than those of patients with ht1 in subjects those did not experience SLE. MDD subjects possessing POMC ht2 achieved remission significantly (P = 0.013; survival analysis) faster than patients with ht1. This study suggests that POMC haplotypes, via an interaction with SLE, are associated with antidepressant treatment outcomes in MDD patients. Regarding SLE, haplotypes of the POMC gene could be useful markers for predicting the response to antidepressant treatment in MDD patients.

Original languageEnglish
Pages (from-to)59-68
Number of pages10
JournalJournal of neural transmission (Vienna, Austria : 1996)
Volume122
Issue number1
DOIs
Publication statusPublished - 2015 Jan 17

Fingerprint

Pro-Opiomelanocortin
Major Depressive Disorder
Polymorphism
Antidepressive Agents
Haplotypes
Genes
Peptide Hormones
Life Change Events
Adrenocorticotropic Hormone
Therapeutics
Survival Analysis
Screening
Genotype
Depression

Keywords

  • Antidepressant
  • Genetic polymorphism
  • Life stress
  • Major depressive disorder
  • Proopiomelanocortin
  • Treatment outcome

ASJC Scopus subject areas

  • Biological Psychiatry
  • Neurology
  • Clinical Neurology
  • Psychiatry and Mental health
  • Medicine(all)

Cite this

The association of proopiomelanocortin polymorphisms with the risk of major depressive disorder and the response to antidepressants via interactions with stressful life events. / Chang, Hun Soo; Won, Eun Soo; Lee, Hwa Young; Ham, Byung-Joo; Kim, Yong Gu; Lee, Min-Soo.

In: Journal of neural transmission (Vienna, Austria : 1996), Vol. 122, No. 1, 17.01.2015, p. 59-68.

Research output: Contribution to journalArticle

@article{24a0b57f8ba84450a9486e3275dfa7b2,
title = "The association of proopiomelanocortin polymorphisms with the risk of major depressive disorder and the response to antidepressants via interactions with stressful life events",
abstract = "Hyperactivity of the hypothalamic–pituitary–adrenal (HPA) axis is among the most consistent neuroendocrine abnormalities in major depressive disorder (MDD). The peptide adrenocorticotropin hormone (ACTH) mediates HPA axis function during stress and is encoded by the proopiomelanocortin (POMC) gene polycistronically. After screening 39 POMC polymorphisms, we evaluated the association of polymorphisms with susceptibility to MDD in 145 MDD patients and 193 normal subjects; in patients, we also evaluated the response to treatment with antidepressants. Additionally, we investigated the role of gene–environment interaction between POMC haplotypes and stressful life events (SLE) in the treatment response. Although genotypes and haplotypes were not significantly associated with the risk of MDD, non-remitters were more likely to carry haplotype 1 (ht1) and to have no ht2 than were remitters (corrected P = 0.010–0.035). Although observations were limited in patients without SLE, a significant haplotype–SLE interaction was observed (P = 0.020). Additionally, at 1, 2, and 8 weeks of treatment, the 21-item Hamilton Depression Rating scores of MDD subjects with POMC ht2 were significantly (P = 0.003–0.044) lower than those of patients with ht1 in subjects those did not experience SLE. MDD subjects possessing POMC ht2 achieved remission significantly (P = 0.013; survival analysis) faster than patients with ht1. This study suggests that POMC haplotypes, via an interaction with SLE, are associated with antidepressant treatment outcomes in MDD patients. Regarding SLE, haplotypes of the POMC gene could be useful markers for predicting the response to antidepressant treatment in MDD patients.",
keywords = "Antidepressant, Genetic polymorphism, Life stress, Major depressive disorder, Proopiomelanocortin, Treatment outcome",
author = "Chang, {Hun Soo} and Won, {Eun Soo} and Lee, {Hwa Young} and Byung-Joo Ham and Kim, {Yong Gu} and Min-Soo Lee",
year = "2015",
month = "1",
day = "17",
doi = "10.1007/s00702-014-1333-9",
language = "English",
volume = "122",
pages = "59--68",
journal = "The BMJ",
issn = "0730-6512",
publisher = "Kluwer Academic Publishers",
number = "1",

}

TY - JOUR

T1 - The association of proopiomelanocortin polymorphisms with the risk of major depressive disorder and the response to antidepressants via interactions with stressful life events

AU - Chang, Hun Soo

AU - Won, Eun Soo

AU - Lee, Hwa Young

AU - Ham, Byung-Joo

AU - Kim, Yong Gu

AU - Lee, Min-Soo

PY - 2015/1/17

Y1 - 2015/1/17

N2 - Hyperactivity of the hypothalamic–pituitary–adrenal (HPA) axis is among the most consistent neuroendocrine abnormalities in major depressive disorder (MDD). The peptide adrenocorticotropin hormone (ACTH) mediates HPA axis function during stress and is encoded by the proopiomelanocortin (POMC) gene polycistronically. After screening 39 POMC polymorphisms, we evaluated the association of polymorphisms with susceptibility to MDD in 145 MDD patients and 193 normal subjects; in patients, we also evaluated the response to treatment with antidepressants. Additionally, we investigated the role of gene–environment interaction between POMC haplotypes and stressful life events (SLE) in the treatment response. Although genotypes and haplotypes were not significantly associated with the risk of MDD, non-remitters were more likely to carry haplotype 1 (ht1) and to have no ht2 than were remitters (corrected P = 0.010–0.035). Although observations were limited in patients without SLE, a significant haplotype–SLE interaction was observed (P = 0.020). Additionally, at 1, 2, and 8 weeks of treatment, the 21-item Hamilton Depression Rating scores of MDD subjects with POMC ht2 were significantly (P = 0.003–0.044) lower than those of patients with ht1 in subjects those did not experience SLE. MDD subjects possessing POMC ht2 achieved remission significantly (P = 0.013; survival analysis) faster than patients with ht1. This study suggests that POMC haplotypes, via an interaction with SLE, are associated with antidepressant treatment outcomes in MDD patients. Regarding SLE, haplotypes of the POMC gene could be useful markers for predicting the response to antidepressant treatment in MDD patients.

AB - Hyperactivity of the hypothalamic–pituitary–adrenal (HPA) axis is among the most consistent neuroendocrine abnormalities in major depressive disorder (MDD). The peptide adrenocorticotropin hormone (ACTH) mediates HPA axis function during stress and is encoded by the proopiomelanocortin (POMC) gene polycistronically. After screening 39 POMC polymorphisms, we evaluated the association of polymorphisms with susceptibility to MDD in 145 MDD patients and 193 normal subjects; in patients, we also evaluated the response to treatment with antidepressants. Additionally, we investigated the role of gene–environment interaction between POMC haplotypes and stressful life events (SLE) in the treatment response. Although genotypes and haplotypes were not significantly associated with the risk of MDD, non-remitters were more likely to carry haplotype 1 (ht1) and to have no ht2 than were remitters (corrected P = 0.010–0.035). Although observations were limited in patients without SLE, a significant haplotype–SLE interaction was observed (P = 0.020). Additionally, at 1, 2, and 8 weeks of treatment, the 21-item Hamilton Depression Rating scores of MDD subjects with POMC ht2 were significantly (P = 0.003–0.044) lower than those of patients with ht1 in subjects those did not experience SLE. MDD subjects possessing POMC ht2 achieved remission significantly (P = 0.013; survival analysis) faster than patients with ht1. This study suggests that POMC haplotypes, via an interaction with SLE, are associated with antidepressant treatment outcomes in MDD patients. Regarding SLE, haplotypes of the POMC gene could be useful markers for predicting the response to antidepressant treatment in MDD patients.

KW - Antidepressant

KW - Genetic polymorphism

KW - Life stress

KW - Major depressive disorder

KW - Proopiomelanocortin

KW - Treatment outcome

UR - http://www.scopus.com/inward/record.url?scp=84933039172&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84933039172&partnerID=8YFLogxK

U2 - 10.1007/s00702-014-1333-9

DO - 10.1007/s00702-014-1333-9

M3 - Article

C2 - 25448875

AN - SCOPUS:84933039172

VL - 122

SP - 59

EP - 68

JO - The BMJ

JF - The BMJ

SN - 0730-6512

IS - 1

ER -